Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Author:
Funder
Biogen Italy
Publisher
Springer Science and Business Media LLC
Subject
Health Policy
Link
http://link.springer.com/content/pdf/10.1186/s12913-019-4264-1.pdf
Reference54 articles.
1. Karampampa K, Gustavsson A, Miltenburger C, Teruzzi C, Fattore G. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler J. 2012;18(2_suppl):29–34. https://doi.org/10.1177/1352458512441566c .
2. Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ. 2006;7:45–54. https://doi.org/10.1007/s10198-006-0385-7 .
3. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86. https://doi.org/10.1212/WNL.0000000000000560 .
4. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009;8:545–59. https://doi.org/10.1016/s1474-4422(09)70082-1 .
5. Dörr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17:354. https://doi.org/10.1007/s11940-015-0354-5 .
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unraveling the complex relationship: Multiple sclerosis, urinary tract infections, and infertility;Multiple Sclerosis and Related Disorders;2024-04
2. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review;Health Economics Review;2024-02-16
3. COST-EFFECTIVENESS OF DISEASE-MODIFYING TREATMENTS FOR MULTIPLE SCLEROSIS IN BULGARIA BASED ON EVIDENCE FROM REAL WORLD SETTINGS;FARMACIA;2023-12-28
4. Immunomodulators as objects of the pharmaceutical market. Message II. Research of the price conjuncture of the retail market segment and economic availability of immunostimulants;Farmatsevtychnyi zhurnal;2023-10-27
5. Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada;Journal of Comparative Effectiveness Research;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3